Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
about
Advances of molecular subtype and targeted therapy of lung cancerKRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)A novel classification of lung cancer into molecular subtypesCopy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseAnal cancer treatment: current status and future perspectives.The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case SeriesGenomic analysis of metastatic cutaneous squamous cell carcinoma.Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?Gene expression profiling analysis of lung adenocarcinomaMolecular characterization of head and neck cancer: how close to personalized targeted therapy?Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.Management of two cases of recurrent anal carcinoma.Review of MicroRNA Deregulation in Oral Cancer. Part I.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceOptimal treatment strategies for anal cancer.Anal cancer: current standards in care and recent changes in practice.Investigational drugs for treating anal cancer and future perspectives.Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer.Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study.YKL-40 and EGFR is a good biomarker for predicting nodal metastasis in anal carcinoma.Background and Current Treatment of Squamous Cell Carcinoma of the Anus.Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.KRAS and BRAF mutations in anal carcinoma.
P2860
Q27030813-64A2611A-71FE-40C6-8A91-0B6AEE0EE7DDQ28541078-2F72B1DE-206F-4D15-9912-C9827831E897Q28731874-1D9A6443-FE91-4A5B-935A-89A68167E6CDQ31096247-35C03416-F4D8-43BA-A036-4F8D6A1DF632Q31162700-6192172F-B1FB-49C1-97A9-937E4C8A42FEQ34465769-59E317C7-D959-49FC-9503-D6AB612F50E2Q35104586-CDFDF0E9-3F2A-4124-853D-7D3FEDC20AC5Q35178368-A36AD1E6-8244-4901-B09F-EC612025F7A9Q35571452-ED6533A9-B163-4252-87D5-94640F762731Q35649008-6036D2F7-5F58-458F-9471-92C6775F7561Q36419182-09B07B9F-A82D-4515-9A8D-FBA9D8253D1DQ36607728-667D3598-0ED2-4FAC-ADA2-75DF5DDD7746Q37000422-906961FA-F1B0-4B92-B393-BD44D218C4F5Q37174058-C8C8B34B-2CB1-4FC1-9A24-1A64D8BE4F34Q37251305-8E212845-DC6C-4844-9ED8-FB134498CB2BQ37454657-2AB433F9-E368-42E5-A11B-BBCF92DDD22BQ38118934-1E9E1AB7-ADB6-4001-B1BA-0917A640FAD4Q38227802-4F5E9609-1EFC-4FCE-A2C6-6CEFEC478638Q38315952-4B5B9E08-65B8-45AE-8F41-D349F4EC4299Q38631415-BC478D91-21B8-4FD1-80EB-90C6DF5D7CEBQ39073840-C250D540-C7FA-4ED8-BA25-C2A10ABB9F17Q39154481-9FC3E29C-E5B2-4E8B-9D1B-423E7FFCF87CQ42322705-4B72F169-A0DC-46AB-992F-14169E60E703Q44990570-9192BB40-A997-4698-8F18-27F30028207BQ47985517-3024906C-5ECE-4A82-89D0-7401E664E0ABQ50897271-FC6DB208-539E-4C8E-9896-BF4070A1DC54Q54979771-8A511941-182A-4306-BA47-D399B263DC38Q55071072-8762C90E-3848-45A3-9133-0B91A1E3A9BB
P2860
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@ast
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@en
Epidermal growth factor recept ...... s of squamous cell carcinomas.
@nl
type
label
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@ast
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@en
Epidermal growth factor recept ...... s of squamous cell carcinomas.
@nl
prefLabel
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@ast
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@en
Epidermal growth factor recept ...... s of squamous cell carcinomas.
@nl
P2093
P2860
P50
P356
P1433
P1476
Epidermal growth factor recept ...... ts of squamous cell carcinomas
@en
P2093
Alain Bols
Filip Baert
Franki Speleman
Jo Van Dorpe
Nancy Van Damme
Patrick Pauwels
Philippe Deron
Pieter Demetter
P2860
P2888
P356
10.1186/1471-2407-10-189
P407
P577
2010-05-11T00:00:00Z
P5875
P6179
1041934271